Evidence map›Paper›PMID 31981039›Full record

ArticleMolecular biotechnology2020

A One-Step Process for the Construction of Phage Display scFv and VHH Libraries.

Carolin Sellmann, Lukas Pekar, Christina Bauer, Elke Ciesielski, Simon Krah, Stefan Becker, Lars Toleikis, Jonas Kügler, André Frenzel, Bernhard Valldorf and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Nanobodies: Robust miniprotein binders in biomedicine.Advanced drug delivery reviews · 2023
    Review
  9. Article
  10. Application Progress of the Single Domain Antibody in Medicine.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Construction of Human Immune and Naive scFv Phage Display Libraries.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carolin SellmannProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Lukas PekarProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Christina BauerProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Elke CiesielskiProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Simon KrahProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Stefan BeckerProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Lars ToleikisProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Jonas KüglerYUMAB GmbH, Inhoffenstraße 7, 38124, Braunschweig, Germany.
André FrenzelYUMAB GmbH, Inhoffenstraße 7, 38124, Braunschweig, Germany.
Bernhard ValldorfChemical and Pharmaceutical Development, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Michael HustYUMAB GmbH, Inhoffenstraße 7, 38124, Braunschweig, Germany.
Stefan ZielonkaProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293, Darmstadt, Germany. Stefan.Zielonka@merckgroup.com.ORCID http://orcid.org/0000-0002-4649-2843

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this work we present a one-step cloning approach for the establishment of antibody phage display libraries relying on type IIs restriction enzymes. We show that single chain variable fragment (scFv) libraries with adequate qualities can readily be cloned in a 'scar-less' manner and that the isolation of antigen-specific antibodies from immunized chickens is feasible within three selection rounds. Moreover, we demonstrate the general applicability of this method by rapidly constructing and panning VHH single domain antibody phage display libraries from immunized Llama repertoires.

Indexed as

AnimalsAntibodiesBacteriophagesCamelids, New WorldCell Surface Display TechniquesChickensDeoxyribonucleases, Type II Site-SpecificErbB ReceptorsEscherichia coliSingle-Chain AntibodiesSingle-Domain AntibodiesAntibodiesDeoxyribonucleases, Type II Site-SpecificEGFR protein, humanErbB ReceptorsSingle-Chain AntibodiesSingle-Domain AntibodiesAntibodyGolden gate cloningPhage displayscFvSingle domain antibodyType IIs enzymeVHH

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.